FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318567053> ?p ?o ?g. }

• W4318567053 endingPage "1597.e4" @default.
• W4318567053 startingPage "1588" @default.
• W4318567053 abstract "The aim of this study was to compare outcomes of single or multistage approach during fenestrated-branched endovascular aortic repair (FB-EVAR) of extensive thoracoabdominal aortic aneurysms (TAAAs).We reviewed the clinical data of consecutive patients treated by FB-EVAR for extent I to III TAAAs in 24 centers (2006-2021). All patients received a single brand manufactured patient-specific or off-the-shelf fenestrated-branched stent grafts. Staging strategies included proximal thoracic aortic repair, minimally invasive segmental artery coil embolization, temporary aneurysm sac perfusion and combinations of these techniques. Endpoints were analyzed for elective repair in patients who had a single- or multistage approach before and after propensity score adjustment for baseline differences, including the composite 30-day/in-hospital mortality and/or permanent paraplegia, major adverse event, patient survival, and freedom from aortic-related mortality.A total of 1947 patients (65% male; mean age, 71 ± 8 years) underwent FB-EVAR of 155 extent I (10%), 729 extent II (46%), and 713 extent III TAAAs (44%). A single-stage approach was used in 939 patients (48%) and a multistage approach in 1008 patients (52%). A multistage approach was more frequently used in patients undergoing elective compared with non-elective repair (55% vs 35%; P < .001). Staging strategies were proximal thoracic aortic repair in 743 patients (74%), temporary aneurysm sac perfusion in 128 (13%), minimally invasive segmental artery coil embolization in 10 (1%), and combinations in 127 (12%). Among patients undergoing elective repair (n = 1597), the composite endpoint of 30-day/in-hospital mortality and/or permanent paraplegia rate occurred in 14% of single-stage and 6% of multistage approach patients (P < .001). After adjustment with a propensity score, multistage approach was associated with lower rates of 30-day/in-hospital mortality and/or permanent paraplegia (odds ratio, 0.466; 95% confidence interval, 0.271-0.801; P = .006) and higher patient survival at 1 year (86.9±1.3% vs 79.6±1.7%) and 3 years (72.7±2.1% vs 64.2±2.3%; adjusted hazard ratio, 0.714; 95% confidence interval, 0.528-0.966; P = .029), compared with a single stage approach.Staging elective FB-EVAR of extent I to III TAAAs was associated with decreased risk of mortality and/or permanent paraplegia at 30 days or within hospital stay, and with higher patient survival at 1 and 3 years." @default.
• W4318567053 created "2023-01-31" @default.
• W4318567053 creator A5003774188 @default.
• W4318567053 creator A5005015562 @default.
• W4318567053 creator A5008352335 @default.
• W4318567053 creator A5008652309 @default.
• W4318567053 creator A5014897513 @default.
• W4318567053 creator A5015301323 @default.
• W4318567053 creator A5017011119 @default.
• W4318567053 creator A5017331770 @default.
• W4318567053 creator A5019096164 @default.
• W4318567053 creator A5019803847 @default.
• W4318567053 creator A5020920575 @default.
• W4318567053 creator A5023443145 @default.
• W4318567053 creator A5024710682 @default.
• W4318567053 creator A5028429089 @default.
• W4318567053 creator A5029419578 @default.
• W4318567053 creator A5029648097 @default.
• W4318567053 creator A5032541644 @default.
• W4318567053 creator A5037643782 @default.
• W4318567053 creator A5039253984 @default.
• W4318567053 creator A5039761037 @default.
• W4318567053 creator A5041027791 @default.
• W4318567053 creator A5042097680 @default.
• W4318567053 creator A5043383232 @default.
• W4318567053 creator A5049144969 @default.
• W4318567053 creator A5049471079 @default.
• W4318567053 creator A5052567263 @default.
• W4318567053 creator A5054836912 @default.
• W4318567053 creator A5055564630 @default.
• W4318567053 creator A5055611097 @default.
• W4318567053 creator A5057446160 @default.
• W4318567053 creator A5059049246 @default.
• W4318567053 creator A5062351892 @default.
• W4318567053 creator A5063900986 @default.
• W4318567053 creator A5065084414 @default.
• W4318567053 creator A5067322805 @default.
• W4318567053 creator A5067721422 @default.
• W4318567053 creator A5072052602 @default.
• W4318567053 creator A5072653695 @default.
• W4318567053 creator A5072717081 @default.
• W4318567053 creator A5074613486 @default.
• W4318567053 creator A5075590880 @default.
• W4318567053 creator A5077273318 @default.
• W4318567053 creator A5078762478 @default.
• W4318567053 creator A5079321693 @default.
• W4318567053 creator A5079656487 @default.
• W4318567053 creator A5081642501 @default.
• W4318567053 creator A5082454665 @default.
• W4318567053 creator A5083732018 @default.
• W4318567053 creator A5084853962 @default.
• W4318567053 creator A5088814765 @default.
• W4318567053 creator A5089306278 @default.
• W4318567053 creator A5089962717 @default.
• W4318567053 creator A5090442172 @default.
• W4318567053 date "2023-06-01" @default.
• W4318567053 modified "2023-10-14" @default.
• W4318567053 title "Comparison of single- and multistage strategies during fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms" @default.
• W4318567053 cites W1571421838 @default.
• W4318567053 cites W1976912209 @default.
• W4318567053 cites W1977328098 @default.
• W4318567053 cites W1995061572 @default.
• W4318567053 cites W2002219404 @default.
• W4318567053 cites W2004127171 @default.
• W4318567053 cites W2005681879 @default.
• W4318567053 cites W2013970909 @default.
• W4318567053 cites W2019453131 @default.
• W4318567053 cites W2036193982 @default.
• W4318567053 cites W2043412210 @default.
• W4318567053 cites W2043576467 @default.
• W4318567053 cites W2061271834 @default.
• W4318567053 cites W2072606109 @default.
• W4318567053 cites W2078725347 @default.
• W4318567053 cites W2160641151 @default.
• W4318567053 cites W2171546308 @default.
• W4318567053 cites W2242903766 @default.
• W4318567053 cites W2396452622 @default.
• W4318567053 cites W2408270188 @default.
• W4318567053 cites W2549292894 @default.
• W4318567053 cites W2611267472 @default.
• W4318567053 cites W2890204925 @default.
• W4318567053 cites W2900254545 @default.
• W4318567053 cites W2914635113 @default.
• W4318567053 cites W2920725521 @default.
• W4318567053 cites W2994819299 @default.
• W4318567053 cites W3003681012 @default.
• W4318567053 cites W3025789723 @default.
• W4318567053 cites W3037104672 @default.
• W4318567053 cites W3044805766 @default.
• W4318567053 cites W3081602352 @default.
• W4318567053 cites W3211732177 @default.
• W4318567053 cites W3214740777 @default.
• W4318567053 doi "https://doi.org/10.1016/j.jvs.2023.01.188" @default.
• W4318567053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36731757" @default.
• W4318567053 hasPublicationYear "2023" @default.
• W4318567053 type Work @default.
• W4318567053 citedByCount "7" @default.
• W4318567053 countsByYear W43185670532023 @default.

• next